Logo
Login

Company Executives

$ Management Team

Mr. David Mott

Independent Chairman of the Board

Age 59
Compensation $186.0K USD
Sex Male

Dr. Martin Huber

President

Chief Executive Officer

Director

Age 65
Compensation $1.614M USD
Sex Male

Mr. Brian Deschuytner

Chief Financial Officer

Chief Operating Officer

Senior Vice President

Age 47
Compensation $1.544M USD
Sex Male

Dr. Timothy Lowinger

Senior Vice President

Chief Science and Technology Officer

Age 61
Compensation $1.401M USD
Sex Male

Dr. Mohan Bala

Senior Vice President

Chief Development Officer

Age 60
Compensation $1.503M USD
Sex Male

Ms. Alejandra Carvajal

Senior Vice President

Chief Legal Officer

Age 51
Compensation $1.360M USD
Sex Female

Board of Directors

From the proxy statement filed Apr 29, 2025
Directors
8
serving now
Independent
0 of 2
stated in the proxy; 6 not stated
Average tenure
8.0 years
from year joined
CEO also chairs the board
No
David Mott
Director Age On board Independent Committees Other public boards 2024 pay Source
Allene M. Diaz
Not stated 2021
4 years
 Not stated
Audit Committee Compensation Committee
Ionis Pharmaceuticals, Inc. $150,996
Andrew A. F. Hack
Not stated 2017
8 years
 Not stated None stated Nuvalent, Inc. Not stated
Kristen M. Hege
Not stated 2016
9 years
 Not stated
Compensation Committee
Adaptimmune Therapeutics plc $154,996
Lawrence M. Alleva
Not stated 2017
8 years
 Not stated
Audit Committee · Chair Nominating and Corporate Governance Committee
Bright Horizons Family Solutions Inc. $164,996
David Mott
Board chair
 Not stated 2012
13 years
 Not stated
Compensation Committee · Chair
Adaptimmune $185,996
Anna Protopapas
Not stated 2015
10 years
 Not independent None stated Nuvalent $145,996
Willard H. Dere
Not stated 2018
7 years
 Not stated
Audit Committee
BioMarin Pharmaceutical Inc. $161,496
Martin Huber
CEO
 Not stated 2020
5 years
 Not independent None stated Syndax Pharmaceuticals, Inc. Paid as CEO

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

No related-party transactions disclosed

The proxy filed Apr 29, 2025 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans